 BEVERLY HILLS, Calif., April 8, 2021 PRNewswire -- GT Biopharma, Inc. NASDAQ: GTBP, a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary NK cell engager TriKETM protein biologic technology platform, is pleased to announce the enrollment of Patient 10 in its GTB-3550 TriKETM first-in-human Phase III clinical trial for the treatment of high-risk myelodysplastic syndromes MDS and refractoryrelapsed acute myeloid leukemia AML. 